Huntington National Bank Sells 560 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Huntington National Bank cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 28.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,386 shares of the medical equipment provider’s stock after selling 560 shares during the quarter. Huntington National Bank’s holdings in Lantheus were worth $124,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in shares of Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after buying an additional 32,551 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in Lantheus by 47.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock worth $1,041,000 after purchasing an additional 3,772 shares during the last quarter. Empirical Asset Management LLC bought a new stake in shares of Lantheus during the 4th quarter valued at about $323,000. Focus Financial Network Inc. purchased a new stake in shares of Lantheus during the 4th quarter valued at about $292,000. Finally, Harbor Capital Advisors Inc. lifted its stake in shares of Lantheus by 12.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 145,379 shares of the medical equipment provider’s stock worth $13,006,000 after purchasing an additional 16,466 shares during the period. Institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on LNTH shares. Truist Financial lifted their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. JMP Securities reissued a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective on the stock. Finally, B. Riley cut their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research note on Friday, March 21st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $129.43.

Insider Transactions at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 64,109 shares of company stock valued at $6,110,806. 2.00% of the stock is currently owned by corporate insiders.

Lantheus Stock Down 6.5 %

NASDAQ:LNTH opened at $90.92 on Monday. The business’s 50-day simple moving average is $93.31 and its two-hundred day simple moving average is $96.03. Lantheus Holdings, Inc. has a 52 week low of $58.46 and a 52 week high of $126.89. The stock has a market cap of $6.23 billion, a PE ratio of 15.13 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.